Defibrotide: Properties and clinical use of an old/new drug

Abstract The drug named defibrotide (DFT) has been studied for many years. It has been shown to possess many activities: profibrinolytic, antithrombotic–thrombolytic, antiischemic (heart, liver, kidney, skin, brain), antishock, antiatherosclerotic, antirejection and anti-angiogenic. The previously d...

Full description

Saved in:
Bibliographic Details
Published in:Vascular pharmacology 2013-07, Vol.59 (1), p.1-10
Main Authors: Pescador, R, Capuzzi, L, Mantovani, M, Fulgenzi, A, Ferrero, M.E
Format: Article
Language:English
Subjects:
Animals
Cardiovascular
Defibrotide
Endothelial activation
Endothelium - drug effects
Fibrinolytic Agents - pharmacology
Fibrinolytic Agents - therapeutic use
Humans
Inflammation
Polydeoxyribonucleotides - pharmacology
Polydeoxyribonucleotides - therapeutic use
Venous occlusive disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The drug named defibrotide (DFT) has been studied for many years. It has been shown to possess many activities: profibrinolytic, antithrombotic–thrombolytic, antiischemic (heart, liver, kidney, skin, brain), antishock, antiatherosclerotic, antirejection and anti-angiogenic. The previously displayed activities, as antithrombotic, profibrinolytic and anti-inflammatory, suggested its use in vascular disorders, as in the treatment of peripheral obliterative arterial disease and in thrombophlebitis. Some years after, the use of DFT in hepatic veno-occlusive disease has been also proposed. Even if DFT was considered for long time a multi-target drug, now it could be considered on the whole as a drug able to protect endothelium against activation. The present work reviews the more important experimental and clinical studies performed to detect DFT effects.
ISSN:1537-1891
1879-3649
DOI:10.1016/j.vph.2013.05.001